[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620957":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":18,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":75,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atropine","EXPERIMENTAL","Children receiving atropine 0.05% eye drops following IOL implantation. (as intervention)",[13],"Drug: Atropine Eye drops",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Children receiving placebo eye drops following IOL implantation.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Atropine Eye drops","Atropine eye drops, 0.05%, will be given following IOL implantation for a period of 12 months.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Rawan Hosny, MSc","CONTACT","+201005556839","rawan.m.hosny@students.kasralainy.edu.eg",[32],{"facility":5,"status":18,"city":33,"state":18,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Cairo","11965","Egypt","EG",{"type":38,"coordinates":39},"Point",[40,41],31.24967,30.06263,{"lat":41,"lon":40},[44],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ahmed Awadein","Professor of Ophthalmology at Cairo University","100620957","myopia-progression-control-using-atropine-005-after-pediatric-cataract-surgery-and-intraocular-lens-implantation-surgery-100620957",false,"NCT07364370","Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery: A Randomized Clinical Trial","Inclusion criteria:\n\n1. Children after IOL implantation (primary or secondary)\n2. Age 1-7 years\n\nExclusion criteria:\n\n1. Eyes with post-operative media opacity hindering adequate assessment of refraction\n2. Eyes with complicated surgeries (e.g. vitreous loss, dropped lens matter requiring PPV, retinal detachment, etc)\n3. Retinal pathologies\n4. Glaucoma (congenital or secondary to surgery)\n5. Anterior or posterior segment anomalies","ALL","1 Year","7 Years",{"count":60,"type":61},50,"ESTIMATED","INTERVENTIONAL",[64],"NA","Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery.\n\nThe investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.",[67,68,69],"Pediatric Cataract","IOL Implantation","Myopia Progression",[71,72,73,74],"pediatric cataract","iol","iol implantation","myopia","NOT_YET_RECRUITING","2026-01-15",{"date":78,"type":79},"2026-01-23","ACTUAL",{"date":81,"type":61},"2026-02",{"date":83,"type":61},"2027-12",{"name":5,"class":6},1]